+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacodynamics, and pharmacokinetics of single or repeat doses of ALN-HTT02 in adults with stage 2 or early stage 3 Huntingtons Disease. This Phase 1 randomized, double-blind, placebo-controlled study focuses on understanding how ALN-HTT02 behaves and is tolerated when administered intrathecally to this patient population. Participants are randomly assigned to receive either a single dose of ALN-HTT02 or a placebo during the double-blind part of the study. Those who receive ALN-HTT02 will not get an additional dose in the open-label part, while placebo recipients have the option to receive a single dose of ALN-HTT02 later. An open-label extension offers participants the chance to receive repeat doses of ALN-HTT02 over a longer period. During the study, participants will be monitored for adverse events for up to 12 months in the double-blind and open-label parts, and up to 36 months in the extension. Researchers will measure levels of mutant huntingtin protein in cerebrospinal fluid and concentrations of ALN-HTT02 in plasma, cerebrospinal fluid, and urine. Safety and tolerability data will be collected throughout the study duration, which runs until 2028, with various clinical evaluations and sample collections at scheduled intervals.

Age: 25Years - 70YearsAll GendersPhase 1
19 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting Enroll-HD, a large, ongoing observational study that combines and expands previous Huntingtons disease HD registries across multiple continents, including Europe, North America, Australasia, and Latin America. This study collects longitudinal clinical data and biological samples from individuals with manifest HD, those carrying or at risk of carrying the HD gene mutation, and control participants without the mutation. The goal is to build a rich database to support research into disease progression, prognosis, and developing clinical trial endpoints. Participants include those with diagnosed HD, pre-manifest carriers, relatives with unknown or negative genotype status, family controls, and community controls. The study involves annual assessments with no planned end date, allowing for long-term data collection. Researchers collect demographic, clinical, family history, genetic, and blood sample information systematically from over 150 sites worldwide. During the study, participants undergo motor, functional, behavioral, and cognitive assessments using standardized tools such as the Unified Huntingtons Disease Rating Scale and Problem Behaviors Assessment-Short. Data are updated at each visit, including clinical signs and genotyping results. The study database is periodically made available to researchers globally, and participants may contribute for many years, helping to advance understanding and support future interventional studies in HD.

Age: 18Years +All Genders
183 locations
H

Actively Recruiting

Healthy Volunteer

Researchers are conducting a long-term observational study called HDClarity to collect cerebrospinal fluid CSF and plasma samples from at least 2,500 participants at various stages of Huntingtons disease HD. The main goal is to gather high-quality CSF samples to study biomarkers and disease pathways that may help develop new treatments for HD. Additionally, plasma samples will be collected to support biomarker research relevant to HD. Participants attend two annual visits a Screening Visit and a Sampling Visit. The Screening Visit involves collecting medical history and clinical data. Those eligible and willing continue to the Sampling Visit, where blood is drawn via venipuncture and CSF is collected through lumbar puncture after fasting for at least six hours or overnight. Some participants may also attend an optional Repeat Sampling Visit 4-8 weeks after the first Sampling Visit during their first year of enrollment. Annual visits continue regularly with a two-month window. Throughout the study, participants health and clinical status are monitored, with the option to skip visits without leaving the study. If a participant misses Sampling Visits for three consecutive years, they may be discontinued but can re-enroll later with consent. The study collects detailed clinical and phenotypic data alongside biological samples to evaluate biomarkers and pathways related to HD, supporting therapeutic development. The study is open-ended and ongoing.

Age: 11Years - 75YearsAll Genders
40 locations
E

Actively Recruiting

Researchers are evaluating whether pridopidine can slow the progression of Huntingtons Disease HD in adults aged 23 to 65. This Phase 3 study compares the effects of pridopidine against a placebo over one year, focusing on overall clinical decline, daily functioning, cognition, motor skills, quality of life, and speech. The study includes participants not currently using antidopaminergic medications and aims to assess safety as well. Participants will first undergo a 1-year randomized, double-blind period where they take either pridopidine or placebo capsules. The treatment begins with a 2-week titration of once-daily dosing, followed by twice-daily dosing for 50 weeks. Following this, all participants who complete the initial year may join a 2-year open-label extension where everyone receives pridopidine, including those originally on placebo. During both periods, participants will attend multiple clinic visits and telephone safety calls. Throughout the study, participants will visit the clinic six times in the first year and six times during the extension, with additional safety phone calls. Researchers will monitor changes in the Unified Huntingtons Disease Rating Scale, functional capacity, motor function, cognition, and quality of life. Safety and tolerability will be closely observed. The total participation period can last up to three years, including both the initial and extension phases.

Age: 23Years - 65YearsAll GendersPhase 3
66 locations
E

Actively Recruiting

Researchers are evaluating SKY-0515, an oral drug, in adults aged 25 and older with genetically confirmed Huntingtons Disease HD. This randomized, double-blind, placebo-controlled trial aims to study the drugs safety, how it affects the body, and its ability to reduce harmful proteins linked to HD. HD is a rare inherited condition caused by a mutation in the HTT gene, leading to nerve cell damage and worsening motor, cognitive, and psychiatric symptoms. SKY-0515 targets reducing mutant huntingtin protein and PMS1 protein, which contribute to disease progression. Participants will be randomly assigned to receive one of three doses of SKY-0515 or a matching placebo once daily by mouth. The treatment period lasts 18 months. The study evaluates multiple doses to find the optimal level for reducing harmful proteins and improving symptoms. The trial is conducted across multiple sites and includes thorough monitoring and testing. During the study, participants will undergo blood tests, MRI scans, and clinical assessments, including the Unified Huntingtons Disease Rating Scale UHDRS. Researchers will measure changes in motor function, total functional capacity, independence, and cognitive tests over 72 weeks. Safety monitoring and efficacy evaluations will continue throughout the treatment, with the main outcome being the change in a composite score of HD symptoms. The trial is expected to be completed by August 2029.

Age: 25Years +All GendersPhase 2Phase 3
31 locations